Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

PURPOSE: The two approved treatments for patients with metastatic melanoma, interleukin (IL)-2 and dacarbazine, mediate objective response rates of 12% to 15%. We previously reported that adoptive cell therapy (ACT) with autologous antitumor lymphocytes in lymphodepleted hosts mediated objective res...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Dudley, Mark E., Yang, James C., Sherry, Richard, Hughes, Marybeth S., Royal, Richard, Kammula, Udai, Robbins, Paul F., Huang, JianPing, Citrin, Deborah E., Leitman, Susan F., Wunderlich, John, Restifo, Nicholas P., Thomasian, Armen, Downey, Stephanie G., Smith, Franz O., Klapper, Jacob, Morton, Kathleen, Laurencot, Carolyn, White, Donald E., Rosenberg, Steven A.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2008
Assuntos:
Immunotherapy
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2652090/
https://ncbi.nlm.nih.gov/pubmed/18809613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.16.5449
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares